A Phase II Open-Label, Ac220 Monotherapy Efficacy Study In Patients with Refractory/Relapsed Flt3-Itd Positive Acute Myeloid Leukemia: Updated Interim Results

被引：0

作者：

Cortes, Jorge E. ^{[1
]}

Perl, Alexander E. ^{[2
]}

Smith, Catherine C. ^{[3
]}

Kovacsovics, Tibor ^{[4
]}

Dombret, Herve ^{[5
]}

Dohner, Hartmut ^{[6
]}

Steffen, Bjorn ^{[7
]}

Pigneux, Arnaud ^{[8
]}

Rousselot, Philippe ^{[9
]}

Krauter, Juergen ^{[10
]}

Martinelli, Giovanni ^{[11
]}

Estey, Elihu H. ^{[12
]}

Burnett, Alan K. ^{[13
]}

Ho, Anthony D. ^{[14
]}

Ifrah, Norbert ^{[15
]}

de Witt, Theo ^{[16
]}

Corringham, Robert ^{[17
]}

James, Joyce ^{[17
]}

Lilienfeld, David ^{[17
]}

Leo, Eugen ^{[17
]}

Gammon, Guy ^{[17
]}

Levis, Mark J. ^{[18
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[2] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[3] Univ Calif San Francisco, Dept Med, Div Hematol Oncol, San Francisco, CA USA

[4] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA

[5] Univ Paris 07, Hop St Louis, AP HP, EA 3518, Paris, France

[6] Univ Ulm, Dept Internal Med 3, D-7900 Ulm, Germany

[7] Klinikum JW Goethe Univ Frankfurt Main, Frankfurt, Germany

[8] CHU Bordeaux, Pessac, France

[9] Univ Versailles St Quentin Yvelines, Hop Versailles, Le Chesnay, France

[10] Hannover Med Sch, D-3000 Hannover, Germany

[11] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy

[12] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA

[13] Cardiff Univ, Sch Med, Cardiff, S Glam, Wales

[14] Univ Heidelberg, Dept Hematol & Oncol, Heidelberg, Germany

[15] CHU Angers, Serv Hematol, Angers, France

[16] Radboud Univ Nijmegen, Med Ctr, NL-6525 ED Nijmegen, Netherlands

[17] Ambit Biosci, San Diego, CA USA

[18] Johns Hopkins Univ, Div Hematol Malignancies, Dept Oncol, Baltimore, MD USA

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1105 / 1105

页数：1

共 50 条

[41] Bisantrene in Combination with Fludarabine and Clofarabine As Salvage Therapy for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)- an Open-Label, Phase II, Study
Danylesko, Ivetta
Shimoni, Avichai
Avigdor, Abraham
Kedmi, Meirav
Shem-Tov, Noga
Yerushalmi, Ronit
Sasson, Maya
Dominissini, Dan
Andersson, Borje S.
Nagler, Arnon
BLOOD, 2023, 142
[42] Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study
Song, Yuqin
Song, Yongping
Liu, Lihong
Zhang, Mingzhi
Li, Zhiming
Ji, Chunyan
Xu, Wei
Liu, Ting
Xu, Bing
Wang, Xin
Gao, Sujun
Zhang, Huilai
Hu, Yu
Li, Yan
Cheng, Ying
Yang, Haiyan
Cao, Junning
Zhu, Zunmin
Hu, Jianda
Zhang, Wei
Jing, Hongmei
Ding, Kaiyang
Lu, Zhengguang
Zhang, Bin
Zhao, Renbin
Xu, Zhixin
Zhu, Jun
BLOOD, 2019, 134
[43] Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation
Ravandi, Farhad
Alattar, Mona Lisa
Levis, Mark J.
Garcia-Manero, Guillermo
Richie, Mary A.
Daver, Naval G.
Faderl, Stefan
Andreeff, Michael
Borthakur, Gautam
Burger, Jan A.
Kadia, Tapan M.
Grunwald, Michael R.
Dellasala, Sara E.
Cortes, Jorge E.
Kantarjian, Hagop M.
BLOOD, 2012, 120 (21)
[44] COMBINATION OF SORAFENIB AND 5-AZACYTIDINE HAS SIGNIFICANT ACTIVITY IN PATIENTS WITH RELAPSED/REFRACTORY OR UNTREATED ACUTE MYELOID LEUKEMIA AND FLT3-ITD MUTATION
Ravandi, Farhad
Alattar, Mona Lisa
Levis, Mark
Garcia-Manero, Guillermo
Richie, Mary A.
Daver, Naval
Faderl, Stefan
Borthakur, Gautam
Burger, Jan
Kadia, Tapan
Grunwald, Michael
Dellasala, Sara
Cortes, Jorge
Kantarjian, Hagop
ANNALS OF HEMATOLOGY, 2013, 92 : S19 - S20
[45] A phase 1/2 study of the oral FLT3 inhibitor pexidartinib in relapsed/refractory FLT3-ITD-mutant acute myeloid leukemia
Smith, Catherine C.
Levis, Mark J.
Frankfurt, Olga
Pagel, John M.
Roboz, Gail J.
Stone, Richard M.
Wang, Eunice S.
Severson, Paul L.
West, Brian L.
Le, Mai H.
Kayser, Sabine
Lam, Bao
Hsu, Henry H.
Zhang, Chao
Bollag, Gideon
Perl, Alexander E.
BLOOD ADVANCES, 2020, 4 (08) : 1711 - 1721
[46] PHASE II STUDY OF SORAFENIB AND 5-AZACYTIDINE (AZA) IN PATIENTS WITH RELAPSED, REFRACTORY OR UNTREATED AML AND FLT3-ITD MUTATION
Ravandi, Farhad
Alattar, Mona Lisa
Levis, Mark
Faderl, Stefan
Burger, Jan
Grunwald, Michael
Cortes, Jorge
Kantarjian, Hagop
ANNALS OF HEMATOLOGY, 2013, 92 : S16 - S16
[47] Efficacy and Safety of Clifutinib, a Novel, Highly Selective, Oral FLT3 Inhibitor, in Patients with FLT3-Mutated Relapsed or Refractory Acute Myeloid Leukemia:Updated Results from a Phase I Study
Jin, Jie
Wang, Huafeng
Yu, Wen-Juan
Ge, Zheng
Wei, Xudong
Li, Yuhua
Jiang, Zhongxing
Li, Yiqing
Du, Xin
Yang, Linhua
Lin, Lie
Wang, Jishi
Yao, Yazhou
Hu, Xiaoping
Lan, Jianping
Deng, Xiuzhi
Chen, Tong
Feng, Xianqi
Li, Dengju
Hou, Ming
Fu, Rong
Huang, Siyong
Wang, Jingbo
Du, Xin
Yang, Hui
Yang, Haiping
Jiang, Yingzhi
Wang, Zhijie
Li, Deng
Liu, Bing
Kang, Ning
Zhuang, Yulei
Zhang, Yingjun
BLOOD, 2023, 142
[48] Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia
Wang, Jianxiang
Jiang, Bin
Li, Jian
Liu, Ligen
Du, Xin
Jiang, Hao
Hu, Jianda
Yuan, Menghe
Sakatani, Taishi
Kadokura, Takeshi
Takeuchi, Masato
Izuka, Shunsuke
Girshova, Larisa
Tan, Jerome
Bondarenko, Sergey N.
Wong, Lily L. L.
Khuhapinant, Archrob
Martynova, Elena
Hasabou, Nahla
Tiu, Ramon V.
BLOOD, 2021, 138
[49] Efficacy and safety of venetoclax in combination with cytarabine and azacitidine (VAA) in relapsed/refractory acute myeloid leukemia: An open-label, single-arm, phase II study.
You, Liangshun
Liu, Yi
Mai, Wenyuan
Zhou, De
Xie, Wanzhuo
Mao, Liping
Zhou, Xinping
Tong, Hongyan
Jin, Jie
Meng, Haitao
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[50] Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial (vol 20, pg 986, 2019)
Cortes, J. E.
Khaled, S.
Martinelli, G.
LANCET ONCOLOGY, 2019, 20 (07): : E346 - E346

← 1 2 3 4 5 →